| CELLECTIS SP.ADR 1 EO-,05 |
| USA |
| Gesundheit |
| US15117K1034 / A14QZE |
| ZVAA (Frankfurt) / CLLS (NASDAQ) |
| FRA:ZVAA, ETR:ZVAA, ZVAA:GR, NASDAQ:CLLS |
| - |
| https://www.cellectis.com.. |
|
Cellectis S.A. - ADR represents American Depositary Receipts of the French biotechnology company Cellectis S.A. This company specializes in the development of gene-editing technologies, particularly focusing on allogeneic CAR-T cell therapies for the..
>Volltext.. |
| 217.6 Mio. EUR |
| 140.7 Mio. EUR |
| 63.25 Mio. EUR |
| -17.7 Mio. EUR |
| -58.83 Mio. EUR |
| -0.59 EUR |
| 103.87 Mio. EUR |
| 55.08 Mio. EUR |
| -34.77 Mio. EUR |
| 1.43 |
| 76.18% |
| -84.24% |
| - |
| - |
| - |
| - |
| CELLECTIS ADR, CELLECTIS |
| 05.04.26 |
|